Parkinson’s disease Pipeline

DelveInsight’s, “Parkinson’s Disease- Pipeline Insight, 2025” report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Parkinson’s disease: Understanding

Parkinson’s disease: Overview

Parkinson’s disease (PD) is a chronic and progressive neurological disorder that primarily affects movement. It is characterized by the gradual loss of dopamine-producing neurons in the substantia nigra, a region of the brain crucial for movement control. PD typically manifests in individuals over the age of 60, though younger onset is possible. It is the second most common neurodegenerative disorder after Alzheimer's disease. The progression of symptoms can vary widely among individuals, making the disease challenging to predict and manage.

 

The hallmark symptoms of Parkinson's disease include tremor, bradykinesia (slowness of movement), rigidity, and postural instability. Tremor often begins in a limb, frequently the hand or fingers, and may occur at rest. Bradykinesia is particularly debilitating, affecting the ability to perform everyday activities. Muscle stiffness or rigidity can cause discomfort and limit the range of motion. Postural instability leads to impaired balance and coordination, increasing the risk of falls. Non-motor symptoms are also common, including sleep disturbances, depression, anxiety, cognitive impairment, and autonomic dysfunction.

   

The exact cause of Parkinson’s disease remains unknown, but it is believed to result from a combination of genetic and environmental factors. Mutations in certain genes, such as LRRK2 and SNCA, have been linked to PD. Environmental factors, including exposure to pesticides and heavy metals, may increase the risk. Pathophysiologically, PD is marked by the aggregation of alpha-synuclein protein into Lewy bodies within neurons. The loss of dopamine in the substantia nigra disrupts the balance of neurotransmitters, leading to the motor and non-motor symptoms of the disease.

 

Diagnosing Parkinson’s disease is primarily clinical, based on medical history and neurological examination. There are no definitive laboratory tests for PD, but imaging studies such as DaTscan can support the diagnosis by showing reduced dopamine transporter activity. Treatment for PD aims to manage symptoms, as there is currently no cure. The cornerstone of treatment is medication, with levodopa being the most effective. Dopamine agonists and MAO-B inhibitors are also used. Advanced cases may benefit from surgical interventions like deep brain stimulation (DBS). Alongside medical treatments, physical therapy, occupational therapy, and lifestyle changes are essential to improve quality of life.

 

"Parkinson’s Disease- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Parkinson’s disease pipeline landscape is provided which includes the disease overview and Parkinson’s disease treatment guidelines. The assessment part of the report embraces, in depth Parkinson’s disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The therapies under development are focused on novel approaches to treat/improve Parkinson’s disease.

 

Parkinson’s disease Emerging Drugs Chapters

This segment of the Parkinson’s disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Parkinson’s disease Emerging Drugs

• Buntanetap: Annovis Bio

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. By improving synaptic transmission, axonal transport, and reducing neuroinflammation, Buntanetap aims to reverse neurodegeneration in AD, PD, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.

 

• Tavapadon: AbbVie

Tavapadon is the first and only selective D1/D5 receptor partial agonist in development for Parkinson’s disease and is currently being studied as a once-daily medicine for use as both a monotherapy and as an adjunctive therapy to LD. Tavapadon is designed to selectively and optimally activate D1/D5 receptors to potentially provide the right balance of motor control, safety and tolerability for patients. By selectively activating D1/D5 dopamine receptors along the nigrostriatal pathway, tavapadon has the potential to offer the right balance of dopamine signaling to improve motor control while avoiding D2/D3 overstimulation, which is believed to underlie many of the side effects of current dopamine agonists. Additionally, as a partial agonist with a 24-hour half-life enabling once-daily dosing, tavapadon may avoid hyper activation of the dopamine receptors, which can lead to troublesome dyskinesias. Currently, the drug is in Phase III trial for the treatment of Parkinson’s disease.

 

• Prasinezumab: Roche

Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. Currently, the drug is in Phase II trial for the treatment of Parkinson’s disease.

 

• GT 02287: Gain Therapeutics

GT-02287, is an allosteric regulator of GCase and is in development for the treatment of PD, with GBA1-PD as the lead indication. The orally administered, brain-penetrant small molecule restores the function of GCase. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced cellular stress in the endoplasmic reticulum, improved lysosomal function and mitochondrial function, reduced toxic glycosphingolipids, aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and improved motor function. Currently, the drug is in Phase I trial for the treatment of Parkinson’s disease.

 

• NNI 362: Neuronascent

NNI-362 is Neuronascent’s patented oral therapeutic aimed at reversing age-related disorders by producing new neurons to replace those lost in chronic neurodegenerative disorders and aging. NNI-362 has a unique mechanism of action (MOA) that provides safety and selectivity specifically for neuron regeneration, and was discovered through Neuronascent’s proprietary phenotypic screening program using human neural progenitors. This MOA takes advantage of the neural progenitors already in the aged brain to promote new neurons and protect them from degeneration in chronic diseases of the aged, specifically Alzheimer’s disease. New neuron regeneration from neural progenitors is a physiologic process in the brain, yet with aging and neurodegenerative disease there begins a pathological insufficiency in generating new neurons that survive to functionality. Thus, NNI-362 is aimed at reversing age-related neuron loss and restoring cognitive function in AD patients, and should also be useful for other disorders of the elderly, including Parkinson's disease and age-related hearing loss. Currently, the drug is in Preclinical trial for the treatment of Parkinson’s disease.

Further product details are provided in the report……..

 

Parkinson’s disease: Therapeutic Assessment

This segment of the report provides insights about the different Parkinson’s disease drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Parkinson’s Disease

There are approx. 130+ key companies which are developing the therapies for Parkinson’s disease. The companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. Phase III include, Annovis Bio.

 

Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

Route of Administration

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Unlock deeper insights into the evolving Parkinson’s disease market landscape—explore market trends, epidemiology, and future forecasts to stay ahead in strategic decision-making.

Parkinson’s disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Parkinson’s disease therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Parkinson’s disease drugs.

 

Parkinson’s disease Report Insights

• Parkinson’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Parkinson’s disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Parkinson’s disease drugs?
• How many Parkinson’s disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Parkinson’s disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Parkinson’s disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Parkinson’s disease and their status?
• What are the key designations that have been granted to the emerging drugs?